Stock Analysis Feb. 13th: AXT Inc, Monster Beverage, BioMarin Pharma, KB Home, Total SA

AXT Inc. (NASDAQ:AXTI): ThinkEquity believes that sales of AXT’s product for wireless markets will recover sooner than expected due to inventory replenishment by cuatomers. The firm expects the company’s other products to also rebound into 2H12, and it predicts that the company’s recovery will be stronger than expected. The firm maintains a Buy rating.

Monster Beverage (MNST): Stifel Nicolaus raised its target on Monster Beverage, citing continued U.S. share gains, international expansion, and innovation going forward. The firm maintains a Buy rating.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN): After attending the WORLD Orphan Disease Conference, RBC Capital expects BioMarin to report positive data for its GALNS and BMN-701 products later this year. The firm recommends buying the stock on pullbacks into the mid or low $30s and maintains an Outperform rating.

KB Home (NYSE:KBH): After meeting with KB Home’s management, RBC Capital believes that the company’s performance is poised to improve significantly. The firm maintains an Outperform rating.

Total SA (NYSE:TOT): Normua believes Total’s Q4 results on Friday were in-line with consensus, and thinks the company’s continued production ramp-up from Pazflor in Angola were positives. However, the firm keeps a Reduce on Total shares due to valuation and continues to prefer Royal Dutch Shell (RDS.A).

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.

To contact the reporter on this story: Derek Hoffman at staff.writers@wallstcheatsheet.com

To contact the editor responsible for this story: Damien Hoffman at editors@wallstcheatsheet.com